You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKinsey
Harvard Business School
Merck
Boehringer Ingelheim

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PERFLUTREN

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Perflutren

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00398281 Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 2006-11-01 RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00398281 Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer Completed Sidney Kimmel Cancer Center at Thomas Jefferson University Phase 3 2006-11-01 RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00507806 Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke Terminated ImaRx Therapeutics Phase 1/Phase 2 2005-03-01 The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Perflutren

Condition Name

Condition Name for Perflutren
Intervention Trials
Hepatocellular Carcinoma 2
Breast Cancer 2
Cystic Kidney Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Perflutren
Intervention Trials
Carcinoma 3
Heart Diseases 2
Carcinoma, Hepatocellular 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Perflutren

Trials by Country

Trials by Country for Perflutren
Location Trials
United States 16
United Kingdom 3
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Perflutren
Location Trials
North Carolina 4
Pennsylvania 4
California 2
Nebraska 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Perflutren

Clinical Trial Phase

Clinical Trial Phase for Perflutren
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Perflutren
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 5
Completed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Perflutren

Sponsor Name

Sponsor Name for Perflutren
Sponsor Trials
National Cancer Institute (NCI) 5
Sidney Kimmel Cancer Center at Thomas Jefferson University 4
National Institutes of Health (NIH) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Perflutren
Sponsor Trials
Other 20
NIH 8
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
Boehringer Ingelheim
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.